Synthetic biology

01Overview and value chain

Markers: [EC: EU GMO Directive 2001/18/EC & NGT Regulation | OECD: Industrial biotechnology & genomics | Regulator: FDA/TSCA (USA), EFSA/EMA (EU), NMPA (China)]

Synthetic biology applies engineering discipline to living cells: it designs DNA, metabolic pathways and genetic circuits on a computer, builds them from synthesised genes in a biofoundry, tests the resulting strains at high throughput, and scales the best ones into chemicals, materials and food ingredients. The field runs on the Design-Build-Test-Learn (DBTL) cycle, where each iteration is automated and data-fed so that strain improvement compounds over time. Its toolkit spans gene synthesis, chassis organisms such as Escherichia coli and Saccharomyces cerevisiae, genetic logic circuits, and biocontainment systems (auxotrophy and kill switches) that keep engineered microbes inside the reactor. By 2026 the field is commercial at scale: Ginkgo Bioworks runs an industrial cell-programming foundry, Twist Bioscience supplies silicon-based synthetic DNA, Genomatica’s bio-BDO delivers 1,4-butanediol with 100% renewable carbon as a drop-in for nylon, and AMSilk’s recombinant spider-silk yarns reached consumer garments in 2026. The market is pulled by decarbonisation of heavy chemistry and by alternative-protein demand, but gated by GMO regulation, especially in the EU where synbio organisms fall under the precautionary GMO directive.

The key directions of synthetic biology are:

1. Metabolic engineering of cell factories: redesigning microbial metabolism to convert sugar, CO2 or methanol into target molecules — drop-in chemicals, alternative proteins and speciality ingredients.
2. Gene synthesis and biofoundries: high-throughput DNA synthesis and automated strain-building platforms that industrialise the Build phase of the DBTL cycle.
3. Genetic circuits and programmable cells: logic-gene circuits that make cells sense signals and respond — biosensors, smart probiotics and cell therapies.
4. Biocontainment and xeno-biology: kill switches, synthetic auxotrophy and recoded genomes that prevent engineered microbes from surviving or exchanging genes outside the reactor.

Sectoral value chain

[Design: AI pathway & gene design] ──> [Build: DNA synthesis & foundry] ──> [Test: screening & fermentation]
                                                   │
                                        (chassis cells: E. coli / yeast)
                                                   │
                                                   ▼
[Purified product] <─── [Scale-up: demo bioreactor] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Gene synthesis platforms: silicon-based DNA synthesis (Twist Bioscience) and cloud gene ordering industrialise the supply of synthetic DNA that feeds every build, cutting cost and turnaround.
• Automated biofoundries: robotic Design-Build-Test-Learn lines (Ginkgo Bioworks) run thousands of strain variants per cycle so improvement compounds with data.
• Genetic firewall biocontainment: synthetic auxotrophy, recoded genomes and kill switches restrict engineered microbes to the reactor, addressing the environmental-release risk that gates GMO approval.

02US

The United States leads synthetic biology through its foundry platforms, DNA-synthesis industry and a regulator that distinguishes engineered microbes under TSCA while funding the field as a national bioeconomy priority.

Ginkgo foundry, Twist DNA synthesis, bioeconomy EO

• Ginkgo Bioworks and the foundry model: Ginkgo runs an industrial cell-programming platform that partners across food, agriculture and chemicals, automating the Design-Build-Test-Learn cycle for customers who buy strains rather than build them.
• Twist Bioscience and DNA supply: Twist manufactures synthetic DNA on a silicon platform and in 2026 launched Complex Genes (early access) for challenging repeat-rich sequences, feeding every downstream build.
• Policy and funding: the 2022 bioeconomy executive order makes synthetic biology a national priority, with DARPA Living Foundries and DOE bioenergy programmes funding strain and pathway engineering.

03CN

China treats synthetic biology as a strategic industrial base, backing national foundries and listed cell-factory companies to displace petrochemicals and secure ingredient supply.

Cathay diacids, national foundries, Bioeconomy strategy

• Cathay Industrial Biotech: Cathay engineers microbes to produce long-chain dibasic acids, a class of biobased monomers for polymers and lubricants, and is a flagship of China’s industrial-synbio push.
• National foundries and hubs: state investment backs genome-synthesis and strain-engineering platforms at Tianjin, Shanghai and Shenzhen, with Yeast 2.0 chromosome synthesis among the visible outputs.
• Regulation: engineered organisms fall under the 2021 Biosafety Law and MARA/MOST oversight, with gene-edited crops handled on a track separate from classical GMOs.

04EU

The European Union develops synthetic biology for the Green Transition — decarbonising heavy chemistry and replacing petrochemicals — but under the strictest GMO regime, which pushes many startups toward US relocation.

AMSilk spider silk, Bio-BDO, precautionary GMO law

• AMSilk and biomaterials: AMSilk produces 100% protein-based recombinant spider-silk yarns that reached consumer garments in 2026, and supplies lightweight biotech materials for aerospace and premium apparel.
• Biobased chemistry and alt-protein: chemical majors integrate synbio for bioplastics and drop-in monomers, while precision-fermentation startups program microbes for animal-free dairy and collagen.
• Precautionary regulation: under EU law synbio organisms are classified as GMOs (Directive 2001/18/EC) and face EFSA risk assessment; the EIC Accelerator funds startups to bridge the “valley of death” to a first demo plant.

05Leading companies and research institutes

06Tech stack and innovations

The synthetic-biology stack joins computational design, automated DNA building and biocontainment into an industrial workflow.

1. Gene synthesis and biofoundries:
   • Silicon-based DNA synthesis (Twist Bioscience) manufactures genes at scale, and Complex Genes extends synthesis to difficult repeat-rich and secondary-structure sequences that long blocked pathway builds.
   • Foundry platforms (Ginkgo Bioworks) automate the Design-Build-Test-Learn cycle so thousands of strain variants are built and screened per cycle, turning strain engineering into a data-compounding industrial process.
2. Metabolic engineering of cell factories:
   • Pathways are redesigned into chassis hosts — E. coli and S. cerevisiae — to convert sugar, methanol or CO2 into target molecules; Genomatica’s bio-BDO delivers a drop-in 1,4-butanediol with fully renewable carbon for nylon and spandex.
   • Cathay Industrial Biotech and Novonesis extend cell-factory production to long-chain dibasic acids and biosolutions, displacing petrochemical routes across polymer, lubricant and ingredient markets.
3. Genetic circuits and biocontainment:
   • Logic-gene circuits let cells sense a signal and respond — biosensors, smart probiotics that deliver therapeutics at a tumour, and optogenetic switches that control cell growth with light.
   • Biocontainment systems — synthetic auxotrophy for non-standard amino acids, recoded genomes and kill switches — restrict engineered microbes to the reactor, the technical answer to the environmental-release risk that gates approval.

07Value chains and production pipelines

DBTL-to-product pipeline for an engineered cell factory (ISO 9001 / GMO-compliant containment)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Design: AI pathway &   │ ───> │ 2. Build: DNA synthesis & │
│    gene design            │      │    foundry assembly       │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Test: high-throughput  │ <─── │ 3. Strain construction in │
│    screening              │      │    chassis host           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Scale-up in demo       │ ───> │ 6. Industrial fermentation│
│    bioreactors            │      │    & downstream product   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Design

Computational tools design the metabolic pathway and gene sequences for the target molecule, using AI and enzyme databases to predict function, flux and toxicity, and outputting a build-ready DNA design.

Stage 2: Build

The designed genes are synthesised on a silicon platform, assembled into pathways in an automated biofoundry, and prepared as construct libraries ready to transform a chassis host.

Stage 3: Strain construction

The pathway libraries are introduced into a chassis — E. coli or yeast — to generate thousands of strain variants, each a candidate cell factory whose performance must be measured.

Stage 4: Test

High-throughput micro-fermentation and mass-spectrometry analytics screen the variant library for titre, rate and yield, ranking strains and feeding the data back into the next design cycle (Learn).

Stage 5: Scale-up

The lead strain is moved to pilot and demonstration bioreactors to validate mixing, gas transfer and process economics, and to lock the downstream purification train before industrial rollout.

Stage 6: Industrial fermentation and product

At commercial scale the production strain ferments feedstock into the target molecule, which is recovered and purified to a biobased chemical, material or ingredient — sold as a drop-in replacement for the petrochemical or animal-derived original.